Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79843.540.6169%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Guardian Pharmacy Services Inc

GRDNNYSE
Trade with Public
Trade with Public
$40.77
0.641.59%
At close: Sep 4, 5:00 PM EST
$40.77
N/A
After Hours: Sep 4, 4:00 PM EST
M&A: Nautilus Pharmacy sold assets to Guardian Pharmacy Service (GRDN) on Tuesday, September 1, 2026
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Guardian Pharmacy Service Analyst Price Targets

Wall Street analyst price targets and consensus rating for Guardian Pharmacy Service (GRDN).

Price Target Range — 7 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingBuy# Analysts5Avg. Consensus PT$41Upside to Avg. PT-0.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 7, 2026OppenheimerMichael WiederhornPT RaiseOutperform$43→$49
Jun 17, 2026Truist SecuritiesDavid MacdonaldPT RaiseBuy$43→$47
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Guardian Pharmacy Service, Raises Price Target to $49

Oppenheimer analyst Michael Wiederhorn maintains Guardian Pharmacy Service (NYSE:GRDN) with a Outperform and raises the price target from $43 to $49.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Guardian Pharmacy Service, Raises Price Target to $47

Truist Securities analyst David Macdonald maintains Guardian Pharmacy Service (NYSE:GRDN) with a Buy and raises the price target from $43 to $47.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Guardian Pharmacy Service, Raises Price Target to $47

B of A Securities analyst Allen Lutz maintains Guardian Pharmacy Service (NYSE:GRDN) with a Buy and raises the price target from $42 to $47.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Guardian Pharmacy Service, Raises Price Target to $43

Oppenheimer analyst Michael Wiederhorn maintains Guardian Pharmacy Service (NYSE:GRDN) with a Outperform and raises the price target from $38 to $43.
Benzinga Newsdesk

This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrades/downgrades/initiations, on Benzinga.
Avi Kapoor

PRO
B of A Securities Initiates Coverage On Guardian Pharmacy Service with Buy Rating, Announces Price Target of $42

B of A Securities analyst Allen Lutz initiates coverage on Guardian Pharmacy Service (NYSE:GRDN) with a Buy rating and announces Price Target of $42.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved